No abstract

No abstract

documenting a CR. Kaplan Meier survival analysis was used to compare recurrence free survival (RFS).RESULTS: CR rate was 45.0%, 86.4% and 69.6% in groups A, B and C, respectively. For patients with smaller tumors (size 1cm 2 ), the CR rate was 50.0%, 87.5% and 77.8%, respectively. For larger tumors (>1cm 2 ), the CR was 40%, 83.3% and 40.0%, respectively. For patients with 3 tumors, the CR rate was 50.0%, 81.3% and 80.0%, while for patients with >3 tumors, the CR rate was 0%, 100% and 50%, respectively. Of the 44 patients with a CR, 36 had follow up data available. Kaplan-Meier survival analysis showed no difference in RFS between groups (log rank test: p¼0.46).CONCLUSIONS: These preliminary results provide an initial indication of the ablative effect of VesiGel and its potential use as an alternative to TURBT. Compared with aqueous MMC 0.1%, VesiGel 0.12% was superior in the treatment of larger and multifocal tumors. Durability data has yet to mature but is promising given the higher predicted 1-year recurrence scores for patients in the VesiGel 0.12% group.

No abstract

No abstract